1. Introduction {#sec1}
===============

Cannabinoid CB1 receptors and relevant endocannabinoids are widely distributed throughout the brain in mediating affective, cognitive, and motor behaviors \[[@B47], [@B62]\]. Much of the current neurochemical evidence suggests that their functional roles are mainly to modulate presynaptic neurotransmission impinging on postsynaptic neurons \[[@B45]--[@B18]\]. Midbrain raphe serotonergic neurons are known as an important substrate of cannabinoids, which have been demonstrated operating in a plethora of neurological responses \[[@B18]--[@B20]\]. Thus, the explicit understanding of cannabinoid modulations on midbrain raphe serotonergic neuronal activity has been for many years one of the central issues in the cannabinoid research.

The dorsal (DRN) raphe nuclei (MRN) are two principal sources of serotonergic projections to the forebrain. The DRN serotonergic projections are likely associated with cognitive and affective activity \[[@B25], [@B26]\] while MRN serotonergic neurons are more clinging to motor behavior \[[@B23], [@B1]\]. Some of the forebrain neurons, particularly GABAergic and glutamatergic afferents, in turn innervate raphe nuclei forming feedback circuits that control extreme fluctuations of 5-HT availability \[[@B46]\]. The convergence of evidence suggests that GABAergic and glutamatergic afferents put different weights on controlling serotonergic activity in two raphe nuclei. GABAergic afferents have a strong and tonic inhibitory influence on serotonergic neurons in the DRN but little to the MRN \[[@B50]--[@B53]\]. However, less is known about the fundamental mechanism underlying neural circuit used by cannabinoids for 5-HT release in the forebrain.

The primary goal of the present study was to determine how 5-HT efflux in somatodendritic and axon terminal regions is altered differently in response to administrations of cannabinoids. This study was carried out in the DRN and one of serotonergic ascending projection sites, namely, nucleus accumbens (NAcc). The second goal was to test the hypothesis that there are direct and indirect effects of cannabinoids on 5-HT efflux in the NAcc. Specifically, the direct effect is simply to inhibit axonal terminal activity via the activation of CB1 receptors, resulting in *reduction* in 5-HT efflux. In contrast, the indirect effect is to disinhibit postsynaptic 5-HT neurons at the DRN involving in GABAergic neurotransmission, resulting in an *increase* in 5-HT efflux. Our results clearly support a conclusion that when cannabinoids are administered systemically in freely behaving animals, the actual 5-HT efflux is determined by the net effect of two opposite actions, resulting in only a *small* increase in 5-HT efflux in the NAcc.

2. Materials and Methods {#sec2}
========================

2.1. Animal Preparation {#sec2.1}
-----------------------

Adult male Sprague-Dawley rats purchased from Charles River Laboratories (Raleigh, NC, USA) were pair housed with food and water available *ad libitum* in a temperature- and humidity-controlled facility and were maintained on a 12 h light/dark cycle (lights on at 08:00 AM). All animal use procedures were in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and the study was specifically approved by the Institutional Animal Care & Use Committee at Florida Atlantic University (Permit number/ID: A10-05). Rats weighing from 300 to 350 g were anesthetized with a combination of xylazine (4 mg/kg i.p.) and ketamine (80 mg/kg i.p.), and then guide cannulae (21-gauge stainless steel tubing) were preimplanted as described previously in detail using standard techniques for stereotaxic surgery \[[@B52]\]. The coordinates for guide cannulae in the DRN were AP 1.2 relative to interaural zero, ML 4.0, and DV 1.0 below the skull surface at a 32° angle lateral to midline; and in the NAcc, AP 10.7, ML 1.4, and DV 1.0 below the skull surface \[[@B40]\]. After implantation, the guide cannulae were plugged with obturators for protection. The animals were allowed a recovery period of at least 1 week before microdialysis.

2.2. Microdialysis {#sec2.2}
------------------

The evening before the experiments, rats were briefly anesthetized with isoflurane, and aseptic dialysis probes were inserted through the guide cannulae. The target coordinates for the tip of the probe were as follows: in the DRN, AP 1.2 mm relative to interaural zero, ML 0.6 mm relative to midline, and DV 5.5--6.4 mm below the skull surface; in the NAcc, AP 10.7 mm, ML 1.4 mm, and DV 6.0--8.5 mm. Rats were then placed in a test chamber and attached to a fluid swivel that allowed animals to move freely. Food and water were available ad libitum. Dialysis probes were perfused overnight with artificial cerebrospinal fluid (aCSF) containing 140 mM NaCl, 3.0 mM KCl, 1.5 mM CaCl~2~, 1.0 mM MgCl~2~, 0.25 mM NaH~2~PO~4~, and 1.0 mM Na~2~HPO~4~. The aCSF was pumped at a rate of 1.0 uL/min. Samples were collected manually, beginning at 10:00 am the following day. Samples were collected at 30-min intervals and analyzed by high-performance liquid chromatography with electrochemical detection (HPLC-EC; EiCOM HTEC-500) in conjugation with an autoinjector (CMA 200). In the 5-HT assay, mobile phase (0.1 M phosphate buffer at pH 6.0, 500 mg/L 1-decanesulfonic acid, 50 mg/L EDTA, and 1.0% methanol) was pumped at a rate of 0.50 mL/min. In the GABA assay, samples were prederivatized with *o*-phthaldialdehyde and 2-methy-2-propanethiol for 10 min at room temperature and then analyzed on a C18 column (100 × 3.2 mm, BASi, USA). The mobile phase consisted of 40% acetonitrile, 0.1 M sodium acetate buffer, and 50 mg/L EDTA at pH 6.0 \[[@B42]\]. The flow rate of GABA separation was set at 0.7 mL/min.

2.3. Procedures of Drug Administration {#sec2.3}
--------------------------------------

To investigate the neural circuit involving in CB1 receptors, drugs were examined by administering to rats through two distinct routes: systemic administration and local infusion. For the systemic administration, WIN 55,212-2, CP 55940, AM251, and SR 147778 being dissolved in saline containing 10% Tween-80 and 20% dimethyl sulfoxide (DMSO) were injected intraperitoneally at a volume of 1 mL/kg in body weight. WIN 55,212-2 mesylate and AM251 were purchased from Tocris Cookson (Ellisville, MO, USA). CP 55940, Tween-80, and DMSO were purchased from Sigma (St. Louis, MO, USA). SR 147778 was obtained from Sanofi-Synthelabo (Paris, France). Control animals were administered with the vehicle that was used to dissolve the drugs. For the local infusion, drugs dissolved in the infusion medium were delivered directly into the DRN or NAcc. Except for experiments in [Figure 3](#fig3){ref-type="fig"}, WIN 55,212-2 was usually dissolved in the artificial cerebrospinal fluid (aCSF) containing 1.5% ethanol and 1.5% cremophor. Cremophor and ethanol were purchased from Sigma. In [Figure 3](#fig3){ref-type="fig"}, WIN 55,212-2 was dissolved in the aCSF containing 1 *μ*M citalopram in addition to 1.5% ethanol and 1.5% cremophor. Note that the purpose of this set of experiments was to test whether cannabinoids could directly inhibit 5-HT efflux released from dendrites in the DRN or from axon terminals in the NAcc. However, 5-HT basal release was already low in the regular microdialysis samples at which an inhibitory response to drugs is not easily detected by measuring reduction in 5-HT efflux. Thus, citalopram, a selective serotonin reuptake inhibitor (SSRI), was employed to elevate the baseline so that reduction in 5-HT efflux, if any, could be reliably measured with the microdialysis approach. Previous studies have demonstrated that citalopram added into the infusion medium at the concentration of 1 *μ*M would not alter the quality of the drug response \[[@B55]\]. Lastly, bicuculline at the concentration of 100 *μ*M was dissolved in the aCSF before infusing into the DRN. Bicuculline was purchased as the methobromide-H~2~O salt from Tocris Cookson (Ellisville, MO, USA). In the control animals, the DRN or NAcc was locally infused with the vehicle (isotonic) that was used to dissolve the drugs.

2.4. Data Analysis {#sec2.4}
------------------

To reduce intersubject variability in group analysis, the data presented in figures are expressed as mean (±S.E.M.) percentage of changes from averaged baseline measurements. Mean baseline 5-HT levels were calculated as the average of four successive samples before drug administration. Statistical analysis was performed by the two-way (drug treatment × time) factorial ANOVA. If significant interactions of drug treatment × time course were found, further statistical analysis was carried out using the one-way ANOVA followed by *post hoc* Scheffe test in determining the significance of the respective time points. The level of *P* value was set at 0.05 for a statistically significant effect.

3. Results {#sec3}
==========

The first set of experiments was to determine whether systemic injection of WIN 55,212-2 (WIN55 hereafter) had an effect on 5-HT efflux in the brain. The doses used in this study were based on behavioral investigations at which the drug was effective to produce conditioning place preference \[[@B11], [@B37]\]. As shown in [Figure 1(a)](#fig1){ref-type="fig"}, WIN55 at 2.5 and 5 mg/kg (i.p.) failed to elicit a significant effect on extracellular 5-HT in the DRN. The conclusion was supported by the two-way ANOVA test revealing that there was no significant effect of treatment doses (*F*~dose~  (2,21) = 1.598, *P* = 0.2258), time (*F*~time~  (5,105) = 1.324, *P* = 0.2599), or interaction of time × doses (*F*~int⁡~  (10,105) = 0.54, *P* = 0.8583). In contrast, the same injection produced a dose- and time-dependent increase in the NAcc ([Figure 1(b)](#fig1){ref-type="fig"}; *F*~dose~  (2,26) = 11.854, *P* = 0.0002; *F*~time~  (5,130) = 5.766, *P* = 0.0002). The *post hoc* Scheffe test showed that the significant effect was apparent 30 min after injection.

CP55940 (CP55 hereafter), which is known for its high affinity to bind cannabinoid receptors \[[@B22]\], was used to reexamine the NAcc response to cannabinoid injection. The dose used in this study was 0.25 mg/kg and 0.5 mg/kg. CP55 at 0.5 mg/kg produced over 50% increases in the NAcc ([Figure 1(c)](#fig1){ref-type="fig"}) but not in the DRN (data not shown). The ANOVA test revealed a significant effect of drug doses (*F*~dose~  (2,24) = 7.185, *P* = 0.0036) and time (*F*~time~  (5,120) = 6.766, *P* = 0.0001). The *post hoc* Scheffe test showed that the significant increase occurred between 0.5 and 1.5 h after the injection.

Next, we tested whether the WIN55-induced increases in 5-HT efflux in the NAcc could be attributable to the activation of CB1 receptors. SR 147778 is a newly synthesized chemical that has a highly potent antagonistic activity at CB1 receptors \[[@B43], [@B16]\]. As shown in [Figure 2(a)](#fig2){ref-type="fig"}, SR 147778 (5 mg/kg, i.p.) alone had no effect on 5-HT in the NAcc. Injection of SR 147778 30 min before WIN55 (5 mg/kg i.p.) blocked the WIN55-evoked increases in 5-HT efflux in the NAcc (*F*~treatment~  (1,9) = 9.457, *P* = 0.0132). This observation was reaffirmed with AM251, a conventional CB1 receptor antagonist \[[@B18]\]. Similarly, AM251 alone had no effect on 5-HT efflux. AM251 pretreatment 30 min before WIN55 significantly blocked the WIN55-elicited increases in 5-HT in the NAcc ([Figure 2(b)](#fig2){ref-type="fig"}; *F*~treatment~  (1,11) = 31.804, *P* = 0.0002).

It has been suggested that endogenous opioidergic system may be one of the substrates responsible for the effect of CB1 receptor agonists in the CNS \[[@B30]--[@B48]\]. Since opioids also cause regional selective effects on 5-HT efflux \[[@B49]\], we tested whether endogenous opioids are involved in the WIN55-induced increases in 5-HT in the NAcc. If this was the case, the opioid receptor antagonist naloxone should be able to antagonize the effect. As shown in [Figure 2(c)](#fig2){ref-type="fig"}, naloxone alone (10 mg/kg, s.c.) had no effect on 5-HT efflux. Naloxone pretreatment failed to block the WIN55-induced increases in 5-HT efflux (*F*~treatment~  (1,14) = 1.579, *P* = 0.2295), suggesting that endogenous opioids did not mediate the effect of cannabinoids on 5-HT efflux.

We suggest that the existence of a neural circuit is responsible for regional selective effects of cannabinoids on 5-HT efflux in the CNS. To test this hypothesis, cannabinoids were directly applied to the DRN or NAcc through microdialysis probes while 5-HT efflux was determined using the same probes. In this set of experiment, 1 *μ*M citalopram was included into the infusion medium to elevate the basal levels of 5-HT efflux. Note that citalopram at such a low concentration would not alter the response of serotonergic neurons to drug administration \[[@B55]\]. As shown in [Figure 3(a)](#fig3){ref-type="fig"}, WIN55 at 100, 300, and 1000 *μ*M infusing into the DRN produced a robust increase in 5-HT efflux in a concentration-dependent manner (*F*~dose~  (3,19) = 5.273, *P* = 0.0081). In contrast, WIN55 infusion directly into the NAcc caused a concentration-dependent reduction in 5-HT efflux in the NAcc ([Figure 3(b)](#fig3){ref-type="fig"}; *F*~dose~  (3,20) = 5.219, *P* = 0.008).

Thus, WIN55 produced two opposite effects on 5-HT efflux in the NAcc, depending on the route of drug administrations. We suggest that the systemic WIN55-induced increases may be due to disinhibition of serotonergic neurons in the DRN. If this was the case, we expected that local infusion of WIN55 to the DRN would also elicit an increase in 5-HT in the NAcc, similar to the systemic injection. To test this, we employed a dual-probe microdialysis technique. As shown in [Figure 4(a)](#fig4){ref-type="fig"}, WIN55 infusion into the DRN caused a concentration-dependent increase in the NAcc (*F*~dose~  (2,18) = 4.256, *P* = 0.0307). Based on evidence that the direct effect of cannabinoids is inhibitory \[[@B57], [@B35]\], we further suggest that the WIN55-induced increases may be due to inhibition of GABAergic neurotransmission on the serotonergic neurons in the DRN. If this was the case, bicuculline, a GABA~A~ receptor antagonist, locally infusing into the DRN would block the inhibitory impact of GABAergic neurotransmission and thereby disrupt the effect of WIN55 on the increased 5-HT efflux. As shown in [Figure 4(b)](#fig4){ref-type="fig"}, bicuculline pretreatment in the DRN abolished the systemic WIN55 (5 mg/kg, i.p)-elicited increases in 5-HT efflux in the NAcc (*F*~treatment~  (1,14) = 3.153, *P* = 0.0975).

Lastly, to confirm the relationship between GABAergic presynaptic responses and cannabinoid administration, we measured changes in GABA efflux in the DRN. As shown in [Figure 5](#fig5){ref-type="fig"}, there was a significant reduction in GABA efflux in the DRN following injection of WIN55 and CP55 (*F*~treatment~  (2,13) = 43.843, *P* \< 0.0001).

4. Discussion {#sec4}
=============

By measuring changes in 5-HT and GABA efflux in the DRN and/or NAcc, this present study demonstrated that there exists a neural circuit in the DRN through which cannabinoids regulate serotonergic neuronal activity in the NAcc. Our data provide evidence demonstrating that cannabinoids can exert both indirect and direct effects on serotonergic neurons; the direct effect of cannabinoids is inhibitory while the indirect effect via presynaptic circuit is excitatory. Despite having opposite effects, we showed that systemic administration of exogenous cannabinoids such as WIN55 and CP55 has a modest excitatory net effect on 5-HT efflux in the NAcc of drug-naïve animals. This is consistent with the reports that the neurophysiologic function of cannabinoids is considered to be a neuromodulator that usually exerts their effect on both local principal neurons and all types of afferents \[[@B18], [@B35], [@B63]\], resulting in a site-specific response \[[@B32]\].

In the DRN, GABAergic and glutamatergic components are two major afferents that synapse onto the serotonergic neurons, controlling 5-HT availability for the forebrain \[[@B46], [@B14]\]. CB1 receptors are found to be widely expressed in the raphe afferents \[[@B18]\] in addition to serotonergic cells \[[@B20]\]. Thus, cannabinoids can exert their effects on all regulatory afferents and principal neurons that form a neural circuit including GABAergic, glutamatergic, and serotonergic components. As such, the change in 5-HT efflux in response to systemic cannabinoids cannot be exclusively a result of the direct action on serotonergic neurons but a complicated integration of inhibitory modulation of both inhibitory and excitatory neurotransmissions impinging on postsynaptic serotonergic neurons. Thus, the effect of cannabinoids on 5-HT release would be a compromised result of excitatory and inhibitory influences, which may explain the findings that there were only modest changes in 5-HT efflux observed in the present study.

The present findings that cannabinoids exert both direct and indirect effects on serotonergic neurons are well consistent with the previous reports that cannabinoids can either reduce \[[@B44], [@B38]\], elevate \[[@B13], [@B17]\], or bidirectionally alter serotonergic activity \[[@B5]\]. Theoretically, the inhibition of glutamatergic afferents would cause a reduction in 5-HT efflux while the inhibition of GABAergic afferents would result in an increase in 5-HT efflux. Therefore, their net effects on serotonergic neurons are likely determined by their relative potency of tonic activity. Physiologically, GABAergic afferents exert spontaneous inhibitory tone on serotonergic neurons while glutamatergic afferents almost have no measurable role in terms of spontaneous action. Note that spontaneous action of glutamatergic afferents is apparent only at a specific behavioral state such as responding to auditory stimulation \[[@B24]\]. Therefore, it is conceivable that modulation of GABAergic afferents would be more prominent on 5-HT efflux than the glutamatergic influence. In general, presynaptic modulation of GABAergic inputs has been suggested to be the key mechanism responsible for several illicit drugs such as opioids, alcohol, and gamma hydroxybutyrate \[[@B52], [@B8], [@B21]\]. In the present study, we suggest that cannabinoids may use the same neural mechanism for their central action, which inhibits GABAergic neurotransmissions to the DRN, thus resulting in disinhibition of serotonergic neurons (disinhibition theory). This may explain our neurochemical data that 5-HT efflux is elevated in the DRN-NAcc pathway following the systemic administration of exogenous cannabinoids.

We demonstrate that changes in 5-HT efflux are dependent not only on doses of cannabinoid injection but also on brain areas examined. Specifically, systemic injection produced approximately a 50--100% increase from baseline 5-HT in the NAcc. In contrast, there was an insignificant effect in the DRN following the same injection. The mechanism for the area-dependent efflux is not clearly understood but likely ascribed to regional circuits in the controlling of postsynaptic 5-HT efflux (see discussion further below) and also due to possible difference in the release of 5-HT in the two regions (see a review by \[[@B2]\]). The release of 5-HT from the serotonergic neurons is believed to take place at axon terminals where 5-HT-containing vesicles can be found. In the DRN, there are numerous recurrent axon collaterals projected from other raphe nuclei, by which serotonergic neurons can be negatively regulated \[[@B33]\]. Recent development of *in vivo* neurochemistry has suggested that dendrites are also equipped with 5-HT-containing vesicles, and many neuroactive chemicals can influence a dendritic release \[[@B7], [@B27]\]. This suggests that 5-HT efflux measured by microdialysis in the DRN is derived from many sources involved in distinct mechanisms including dendritic release, recurrent axon collateral release, and axon terminal release. Although it is difficult to determine the amounts of each release contributing to the 5-HT efflux in the DRN, it is conceivable that dendritic release may be an important component in the extracellular measurement. Much of available evidence suggests that the properties of dendritic release may be different from that at axons in the forebrain. For instance, the spontaneous 5-HT release is relatively higher in the DRN compared with that from axon terminals \[[@B53], [@B6]\]. It is known that the receptor subtype expression is different between the somatodendritic sites and axon terminals of serotonergic neurons \[[@B50], [@B28]\]. Altogether, drugs that cause changes in 5-HT efflux at somatodendritic sites of the DRN would not necessarily produce the same response in forebrain areas that contain exclusively the axon terminals.

We found that the neurochemical response to cannabinoids is depending on the route of drug administration. Unlike systemic injection, local application of cannabinoids to the NAcc failed to produce the increase in 5-HT. Instead, 5-HT efflux was reduced ([Figure 3(b)](#fig3){ref-type="fig"}). It should be kept in mind that citalopram at the concentration of 1 *μ*M was added in the infusion medium into the NAcc. After the addition of citalopram, the basal level of 5-HT efflux before drug administration was elevated to \~4 pg/sample, almost 10 times greater than the physiological level. Since citalopram effectively blocks reuptake of extracellular 5-HT released from local circuitry, a small reduction in 5-HT efflux can be, therefore, sensitively determined. This pharmacological approach has been widely employed in the *in vivo* 5-HT research using microdialysis techniques. Furthermore, it has been demonstrated that a local application of citalopram at such a low concentration did not alter responsivity of serotonergic neurons to drug administration when the data were expressed as percentage changes relative to baseline \[[@B55]\]. For comparison, citalopram was also infused into the DRN for investigating the effects of cannabinoids on 5-HT efflux in the DRN. As a result, WIN55 caused a concentration-dependent increase in the DRN but a decrease in the NAcc. This further supports that neural circuits that control 5-HT release in response to cannabinoids are different in two regions, regardless the addition of citalopram in the infusion medium. Previous *in vitro* studies demonstrated that cannabinoids decrease 5-HT release from axon terminals \[[@B45], [@B38]\]. This effect can be ascribed to a direct inhibitory activation of CB1 receptors located on the axon terminals. Alternatively, excitatory presynaptic influence from glutamatergic afferents may be inhibited by cannabinoid application, as suggested in one study \[[@B44]\]. However, there is no evidence implicating that 5-HT axon terminal in this region is tonically controlled by glutamatergic afferents. Thus, reduction in 5-HT efflux can be considered to be a direct inhibitory effect of cannabinoids on serotonergic axon terminals as suggested in the previous studies \[[@B37], [@B38]\]. This is consistent with the observation that CB1 receptors are expressed in the axon terminals that might directly respond to cannabinoids \[[@B20]\].

In the present study, we found that the local infusion of WIN55 into the DRN produced an increase in 5-HT in both the DRN and NAcc. These observations are in agreement with findings that excitatory stimulation of the DRN serotonergic cells results in an increase in extracellular 5-HT in the NAcc \[[@B51], [@B29]\]. Our data suggest that a CB1 receptor-mediated neural circuit that directly controls 5-HT release and transmission through the DRN-NAcc pathway would be activated by cannabinoids in the DRN. The effect was apparent in response to 300 *μ*M and 1000 *μ*M, but not 100 *μ*M WIN55. In this regard, relatively high concentrations of WIN55 were used during the local infusion for two reasons. First, the microdialysis membrane served as a barrier to the region of the brain. It has been demonstrated with a 1-mm microdialysis probe that only \~7% of infused substances can cross the barrier as examined in an *in vitro* study \[[@B49]\]. Second, the viscosity of the organic solvent in which WIN55 was dissolved was relatively high, which might have dampened the diffusion of the drug across the probe membrane. Thus, it was necessary to utilize high concentrations in the infusion medium that drugs could effectively follow concentration gradients diffusing into local brain tissue.

Finally, we presented evidence that GABAergic neurotransmission in the DRN is the major neural target for cannabinoid regulation, which is responsible for changes in 5-HT efflux of the DRN-NAcc pathway. This view is strengthened by the observation that GABAergic neurons have a strong tonic inhibition on serotonergic neurons in the DRN \[[@B53], [@B51]\]. Thus, although the action of cannabinoids in the circuit appears to have multiple sites including GABAergic and glutamatergic and serotonergic neurons \[[@B18], [@B17], [@B34]\], the net consequence would be that serotonergic neurons are disinhibited resulting in an increase in 5-HT efflux in the regions receiving DRN projections. This hypothesis was experimentally approved in this study by testing with bicuculline, a GABA~A~ receptor antagonist, in which blocking GABA activation in the DRN abolished the increase in 5-HT in the NAcc ([Figure 4](#fig4){ref-type="fig"}). Previous studies have shown that cannabinoids could reduce GABA efflux or GABA-mediated spontaneously inhibitory postsynaptic currents in many brain regions including but not limited to frontal cortex, pallidus, substantia nigra, and hippocampus \[[@B10]--[@B9]\]. In the present study, we measured changes in GABA efflux in the DRN, demonstrating that the reduction in GABA efflux was in correlation with the increase in 5-HT efflux, further supporting the role of GABAergic neurotransmission in the DRN-NAcc serotonergic pathway. Collectively, systemic administration of cannabinoids may exert two opposite effects on serotonergic neurotransmission, resulting in a small increase in 5-HT efflux in the NAcc.

This work was supported by the NIH grant no. R15DA029863. The authors acknowledge the assistance of Ellison Pearson and Nandini Rambahal in the neurochemical assay.

![Systemic effect of CB1 receptor agonists on 5-HT efflux in the DRN and NAcc. Data are expressed as percent of average baseline values (% mean ± s.e.m.). Mean baseline level of extracellular 5-HT was 0.62 ± 0.02 pg/sample in the DRN (*n* = 24) and 0.31 ± 0.01 pg/sample in the NAcc (*n* = 44). The arrow indicates the time of the injection. (a) Systemic injection of WIN 55,212-2 (2.5 and 5 mg/kg, i.p.) had no effect on extracellular 5-HT in the DRN. (b) Systemic injection of WIN 55,212-2 (2.5 and 5 mg/kg, i.p.) produced dose- and time-dependent effects on extracellular 5-HT in the NAcc. (c) Systemic injection of CP55940 (0.25 and 0.5 mg/kg, i.p.) produced dose- and time-dependent effects on extracellular 5-HT in the NAcc. \**P* \< 0.05 and \*\*\**P* \< 0.001 versus vehicle examined by the repeated measures ANOVA followed by the post hoc Scheffe test.](ISRN.PHARMACOLOGY2012-276902.001){#fig1}

![Effects of CB1 and opioid receptor antagonists on WIN 55,212-2-induced increases in 5-HT in the nucleus accumbens. Data are expressed as percent of average baseline values (% mean ± s.e.m.). Mean baseline level of extracellular 5-HT was 0.39 ± 0.04 pg/sample in the NAcc (*n* = 45). The arrows indicate the time of injection of antagonists 30 min before WIN 55,212-2. The effect of WIN 55,212-2 on 5-HT efflux in the NAcc was blocked by SR 147778 (5 mg/kg i.p.; (a)) and AM251 (5 mg/kg, i.p; (b)), but not by naloxone (10 mg/kg, s.c.; (c)). \**P* \< 0.05 and \*\*\**P* \< 0.001 versus vehicle examined by the repeated measures ANOVA followed by post hoc Scheffe test.](ISRN.PHARMACOLOGY2012-276902.002){#fig2}

![Effect of reverse dialysis infusion of WIN 55,212-2 on 5-HT efflux in the DRN (a) or NAcc (b). Data are expressed as percent of average baseline values (% mean ± s.e.m.). Note that 1 *μ*M citalopram was included in the infusion medium. Mean baseline level of extracellular 5-HT was 3.35 ± 0.06 pg/sample in the DRN (*n* = 23) and 4.15 ± 0.79 pg/sample in the NAcc (*n* = 24). The open horizontal bars indicate the 30-min period of drug infusion. (a) WIN 55,212-2 (100, 300 and 1000 *μ*M) produced a concentration-dependent increase in 5-HT efflux in the DRN. (b) WIN 55,212-2 (100, 300, and 1000 *μ*M) produced a concentration-dependent decrease in 5-HT efflux in the NAcc. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001 versus vehicle examined by the repeated measures ANOVA followed by post hoc Scheffe test.](ISRN.PHARMACOLOGY2012-276902.003){#fig3}

![Data are expressed as percent of average baseline values (% mean ± s.e.m.). Mean baseline level of extracellular 5-HT was 0.39 ± 0.06 pg/sample in the NAcc (*n* = 37). (a) Effect on 5-HT efflux in the NAcc of reverse dialysis infusion of WIN 55,212-2 in the DRN. The open horizontal bars indicate the 30-min period of drug infusion. WIN 55,212-2 (300 and 1000 *μ*M) in the DRN produced a concentration-dependent increase in 5-HT efflux in the NAcc. \**P* \< 0.05 and \*\**P* \< 0.01 versus vehicle examined by the repeated measures ANOVA followed by post hoc Scheffe test. (b) Effect on the WIN 55,212-2-induced increases in 5-HT efflux in the NAcc mediated by the reverse dialysis infusion of bicuculline (100 *μ*M) in the DRN. Systemic injection of WIN 55,212-2 at 5 mg/kg i.p. took place at time zero. Bicuculline pretreatment in the DRN blocked the systemic effect of WIN 55,212-2 on 5-HT efflux in the NAcc.](ISRN.PHARMACOLOGY2012-276902.004){#fig4}

![Effect of systemic cannabinoids on GABA efflux in the DRN. The arrow indicates the time of injection of 5 mg/kg WIN 55,212-2, 0.5 mg/kg CP55940, or vehicle at *t* = 0 minutes. Data are expressed as percent of average baseline values (% mean ± s.e.m.). Mean baseline level of extracellular GABA was 0.32 ± 0.06 pmol/sample. There was a significant reduction in GABA efflux in the DRN following systemic injection of WIN 55,212-2 or CP55945. \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001 versus vehicle examined by the repeated measures ANOVA followed by post hoc Scheffe test.](ISRN.PHARMACOLOGY2012-276902.005){#fig5}
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